List of Eysuvis drug patents

Eysuvis is owned by Kala Pharms Inc.

Eysuvis contains Loteprednol Etabonate.

Eysuvis has a total of 13 drug patents out of which 0 drug patents have expired.

Eysuvis was authorised for market use on 26 October, 2020.

Eysuvis is available in suspension/drops;ophthalmic dosage forms.

Eysuvis can be used as a method for delivering a composition to a mucus membrane, administration to the eye of a patient for treatment of dry eye condition, a method for treating dry eye in a patient, a method for delivering a pharmaceutical agent across a mucosal barrier.

The generics of Eysuvis are possible to be released after 03 May, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11219596 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10857096 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10945948 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10940108 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US9532955 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US9737491 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US9056057 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US9827191 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10058511 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US10993908 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US10688045 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

US9393213 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(10 years from now)

US10646436 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 26, 2023

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 26 October, 2020

Treatment: A method for treating dry eye in a patient; A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the eye of a patient for treatment of dry eye condition

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in